Grace Therapeutics, Inc. Increase (Decrease) in Accounts Payable, Trade
Grace Therapeutics, Inc. (GRCE) reported Increase (Decrease) in Accounts Payable, Trade of -$897.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-13
- Grace Therapeutics, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was -$897.00K, a 226.16% decline year-over-year.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was $863.00K.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was $36.00K.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was -$1.07M, a 1503.95% decline year-over-year.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable, trade for fiscal 2026 was $543.00K.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable, trade for fiscal 2025 was -$84.00K.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable, trade for fiscal 2024 was -$1.65M, a 501.95% decline from fiscal 2023.
- Grace Therapeutics, Inc. increase (decrease) in accounts payable, trade for fiscal 2023 was $411.00K.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 3 month as first filed | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$897.00K 10-Q · filed 2026-08-13 | -$34.00K derived: sum of 2 quarters · filed 2026-08-13 | $2.00K derived: sum of 3 quarters · filed 2026-08-13 | -$1.06M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $863.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $899.00K derived: sum of 2 quarters · filed 2026-06-18 | -$168.00K derived: sum of 3 quarters · filed 2026-06-18 | $543.00K 10-K · filed 2026-06-18 | |
| 2025-12-31 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | -$1.03M derived: sum of 2 quarters · filed 2026-02-12 | -$320.00K 10-Q · filed 2026-02-12 | -$691.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-09-30 | -$1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | -$356.00K 10-Q · filed 2025-11-13 | -$727.00K derived: sum of 3 quarters · filed 2026-08-13 | -$1.43M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $711.00K 10-Q · filed 2026-08-13 | $340.00K derived: sum of 2 quarters · filed 2026-08-13 | -$363.00K derived: sum of 3 quarters · filed 2026-08-13 | -$287.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$371.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | -$1.07M derived: sum of 2 quarters · filed 2026-06-18 | -$998.00K derived: sum of 3 quarters · filed 2026-06-18 | -$84.00K 10-K · filed 2026-06-18 | |
| 2024-12-31 | -$703.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | -$627.00K derived: sum of 2 quarters · filed 2026-02-12 | $287.00K 10-Q · filed 2026-02-12 | $226.00K derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-09-30 | $76.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $990.00K 10-Q · filed 2025-11-13 | $929.00K derived: sum of 3 quarters · filed 2025-11-13 | $1.32M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $914.00K 10-Q · filed 2025-08-12 | $913.00K 10-Q · filed 2024-08-09 | $853.00K derived: sum of 2 quarters · filed 2025-08-12 | $1.25M derived: sum of 3 quarters · filed 2025-08-12 | $711.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | $334.00K derived: sum of 2 quarters · filed 2025-06-23 | -$203.00K derived: sum of 3 quarters · filed 2025-06-23 | -$1.65M 10-K · filed 2025-06-23 | |
| 2023-12-31 | $395.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | -$142.00K derived: sum of 2 quarters · filed 2025-02-13 | -$1.59M 10-Q · filed 2025-02-13 | -$1.66M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-09-30 | -$537.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-13 | -$1.99M 10-Q · filed 2024-11-13 | -$2.05M derived: sum of 3 quarters · filed 2024-11-13 | ||
| 2023-06-30 | -$1.45M 10-Q · filed 2024-08-09 | -$1.52M derived: sum of 2 quarters · filed 2024-08-09 | |||
| 2023-03-31 | -$67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21 | $411.00K 10-K · filed 2024-06-21 | |||
| 2022-12-31 | $478.00K 10-Q · filed 2024-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |